Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
5(62.5%)
Phase 2
3(37.5%)
8Total
Phase 1(5)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT05028127Phase 1Completed

A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects

Role: lead

NCT02610543Phase 2Terminated

UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome

Role: lead

NCT00899678Phase 2Terminated

The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents

Role: lead

NCT02430909Phase 2Completed

Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis

Role: lead

NCT02220153Phase 1Completed

A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers

Role: lead

NCT02141763Phase 1Completed

Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis

Role: lead

NCT02529956Phase 1Completed

A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis

Role: lead

NCT02207595Phase 1Completed

Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects

Role: lead

All 8 trials loaded